title: Atypical femoral fractures bilaterally in a patient receiving denosumab.
authors.affiliation: Department of Orthopedics , Broomfield Hospital, Essex , UK ;
authors.forename: Efstathios
authors.initials: E
authors.lastname: Drampalos
authors.forename: George
authors.initials: G
authors.lastname: Skarpas
authors.forename: Nikos
authors.initials: N
authors.lastname: Barbounakis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Michos
mesh_terms: D000368:Aged; D019386:Alendronate / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000069448:Denosumab; D004334:Drug Administration Schedule; D005260:Female; D005264:Femoral Fractures / Q000139:chemically induced* / Q000000981:diagnostic imaging; D015775:Fractures, Stress / Q000139:chemically induced* / Q000000981:diagnostic imaging; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D058866:Osteoporotic Fractures / Q000517:prevention & control; D011859:Radiography
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D000069448:Denosumab; D019386:Alendronate